Share Name Share Symbol Market Type Share ISIN Share Description
Hutchison China Meditech LSE:HCM London Ordinary Share KYG4672N1016 ORD USD1
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -245.00p -5.51% 4,200.00p 4,150.00p 4,250.00p 4,382.50p 4,175.00p 4,382.50p 20,008 15:25:44
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 175.0 -38.3 16.2 277.4 2,551.51

Hutchison China Meditech (HCM) Latest News (1)

More Hutchison China Meditech News
Hutchison China Meditech Takeover Rumours

Hutchison China Meditech (HCM) Share Charts

1 Year Hutchison China Meditech Chart

1 Year Hutchison China Meditech Chart

1 Month Hutchison China Meditech Chart

1 Month Hutchison China Meditech Chart

Intraday Hutchison China Meditech Chart

Intraday Hutchison China Meditech Chart

Hutchison China Meditech (HCM) Discussions and Chat

Hutchison China Meditech Forums and Chat

Date Time Title Posts
19/10/201717:53(Chi-Med)Hutchinson China Meditech Limited1,116
13/6/201707:54Hutchison China Meditech- CHARTS AND DISCUSSION74

Add a New Thread

Hutchison China Meditech (HCM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2017-10-19 16:15:004,500.004,030181,350.00OK
2017-10-19 16:15:004,500.004,030181,350.00OK
2017-10-19 16:15:004,500.003,000135,000.00OK
2017-10-19 16:15:004,500.003,000135,000.00OK
2017-10-19 15:29:384,200.0014588.00O
View all Hutchison China Meditech trades in real-time

Hutchison China Meditech (HCM) Top Chat Posts

Hutchison China Meditech Daily Update: Hutchison China Meditech is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker HCM. The last closing price for Hutchison China Meditech was 4,445p.
Hutchison China Meditech has a 4 week average price of 3,635p and a 12 week average price of 3,375p.
The 1 year high share price is 4,570p while the 1 year low share price is currently 1,820p.
There are currently 60,750,132 shares in issue and the average daily traded volume is 19,603 shares. The market capitalisation of Hutchison China Meditech is £2,551,505,544.
learningtrader: Given the quiet nature of the board - other than when the share price spikes - I took a position two months ago when it hit GBP 40. I have been trading this on and off for the last 5 years but unfortunately I wish I had just bought and held. Question for Nerdofsteel and MAd Foetus: In due course (and I mean very long term) do you foresee this to be a GBP 20 Billion company?
nerdofsteel: The number of watchers, and the correpsonding number of posts on Stocktwits (one of the main U.S. Retail Investor Bulletin Boards) has incerased dramatically in the last week, coupled with yesterday's large volumes. Positions being taken......... As I said on post 1018, you only have to look at the fiarly accurately forecast revs and EBITDA numbers to see where we will be, bearing in mind the U.S. market are in contyrol of the share price, and unlike the UK market, the U.S completely get how to value Biotechs, as they effectively invented the process and the nPV formulas. Also worth looking at HCM's track record over the last 10 years and you will see what they've delivered. The Directors keep buying for a simple reason............they know where this is going in trhe medium to lonmg term but don't care much about the short term - after all, they are in the drug development business One more thing to note - the CEO said at the time of the interims that they were working on 2 or 3 things, any one of which would DRAMATICALLY change 2017 guidance Look at the deal Beigene has done with Celgene and you will see the potential deal
nerdofsteel: "What price would you advise buying at?" Any, I mean the share price has grown in excess of 2000% in the last 10 years and we don't have a drug on the market, yet, although our first application has been submitted to the CFDA, so expect launch next year, followed by a number of others. If you look at a P/S of say 14 and a P/E of say 70 (Genmab is a great peer to compare HCM to) you can see Analysts forecasting sales of circa $650m by 2020 which equates to $9,100m mcap or circa £108 per share ish. So if anyone has a long term view like me (8 - 10 yrs) this is a bargain, even at this price IMO
reptile3: I think those who keep an eye on technical analysis would say the share price was bound to visit £36 (or thereabouts), being on a projected line of support before resuming its upward move. If this is correct we should experience a day or two of stability followed by a significant rebound next week to maybe £41 or £42..... IMHO
nimrod22: Looks as if the share price is going to pull back further.......and hopefully have another rally in a couple of weeks
mad foetus: More director buys. I tried a cheeky top up online but none available. Await the inevitable news and a £50 share price over the next couple of months
nerdofsteel: I agree dbadvn although for me price swings are irrelevant as I've been invested and have been building a position for 10 years and will continue for the next 10 years. 2000% in the last 10 years has demonstrated that, over the long term, the Company delivers. I agree with your point about NASDAQ and US Analysts, as that is what is controlling the share price. The London listing is now irrelevant and I can see a time when they de-list as it serves no real purpose at all.
nerdofsteel: Growth over the last 10 years has been astonishing and Simon To is right to state “Chi-Med’;s consistent strategy over the past 16 years has generated considerable shareholder value" - to the tune of 2000% However, I think he is also right to suggest that if you think that is astonishing, you ain't seen nothing yet! The CEO said recently they were working on 2 or 3 big things any one of which will radically change 2017 guidance. That suggests a major Big Pharma licencing deal is on the cards like the recent Beigene/Celgene one announced 2 weeks ago, prompting Beigene's share price to go up 75%
nerdofsteel: "The relative ignorance in the US about the company’s potential makes it a great investment right now" This article offers a great perspective for those looking to invest for the long term, and by that I mean 5 years + And it is the U.S share price that mainly drives the UK share price now, as volumes are usually bigger on NASDAQ
nerdofsteel: The LSE share price tanked because the NASDAQ IPO (2 x ADR's per AIM Ordinary share) was priced below what was originally expected, presumably because the Institutions taking up the offer wouldn't pay the full price. The effect was the London share price tanked overnight. Now Institutions are starting to buy on NASDAQ, because they can see exactly how valuable the pipeline is and that this Company is unique in the Biotech space eg. it actually generates cash. The bb is quiet because there are very very few Private Investors, most are instutions (it is Mark Slater's largest holding in his growth fund. CK Hutchison hold 60%. IMO most private Investors do not invest because drug development is a very very long term game. However, after 14 years we have our first drugs coming to the market next year and these will be Blockbusters with peak annual sales potential of $100's millions Looking at the sales forecasts, using standard valuations of P/E, P/S, nett margis etc it is my view we will have a mcap in excess of $10bn within the next 5-10 years
Hutchison China Meditech share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20171020 03:09:46